The images describe fields related to **Palliative Chemotherapy**, which focuses on relieving symptoms and improving the quality of life for patients with advanced cancer. Here's a structured explanation:

### **General Information**

1. **Patientennummer**:
   * Unique identifier for the patient.

### **Radiotherapy and Chemotherapy**

1. **Radiotherapie**:
   * Indicates whether radiotherapy was used.
2. **Strahlenmenge in Gray**:
   * Total radiation dose administered, measured in Gray (Gy).
3. **Chemotherapie**:
   * Indicates whether chemotherapy was part of the treatment.
4. **Anzahl der Zyklen**:
   * Number of chemotherapy cycles administered.

### **Specific Chemotherapeutic Agents**

1. **5-Fluorouracil**:
   * Common chemotherapy drug.
2. **Capecitabin**:
   * Oral prodrug of 5-Fluorouracil.
3. **Oxaliplatin**, **Cisplatin**, **Carboplatin**:
   * Platinum-based drugs for various cancers.
4. **Epirubicin**, **Doxorubicin**:
   * Anthracycline drugs used for breast and other cancers.
5. **Gemcitabin**, **Docetaxel**, **Paclitaxel**, **Irinotecan**:
   * Various chemotherapy drugs for pancreatic, breast, ovarian, and colorectal cancers.
6. **Sorafenib**:
   * Targeted therapy for liver and kidney cancers.
7. **Folinsäure**:
   * Used alongside 5-Fluorouracil for efficacy enhancement.
8. **Andere Chemotherapeutika I, II, III**:
   * Other unspecified chemotherapy agents.

### **Interventional Therapies**

1. **TACE (Transarterial Chemoembolization)**:
   * Localized treatment for liver tumors.
2. **RFA (Radiofrequency Ablation)**:
   * Minimally invasive tumor destruction technique.
3. **Photodynamische Therapie (PDT)**:
   * Light-based cancer treatment.
4. **TACE Zyklen**, **RFA Zyklen**, **PDT Zyklen**:
   * Number of cycles for respective therapies.

### **Treatment Outcomes**

1. **Stabiler Verlauf**:
   * Stable disease with no progression or shrinkage.
2. **Progression**:
   * Indication of disease progression.
3. **Regression**:
   * Tumor shrinkage as a response to treatment.
4. **Remission**:
   * Complete or partial disappearance of cancer symptoms or markers.

### **Tumor Board Recommendations**

1. **Tumorboardbeschluss**:
   * Decision made by the tumor board.
2. **Empfehlungen TuBo**:
   * Recommendations from the tumor board.
3. **Umsetzung TuBo**:
   * Implementation of tumor board decisions.

### **Dosage Adjustments**

1. **Dosis nach KOF**:
   * Dose calculated based on body surface area (Körperoberfläche).
2. **Primäre Dosisreduktion**:
   * Initial reduction in the prescribed dose.
3. **Dosisreduktion im Verlauf**:
   * Dose reductions during the treatment course.

### **Side Effects**

1. **Nebenwirkung der CX**:
   * Side effects of chemotherapy.
2. **Emesis**:
   * Vomiting as a side effect.
3. **Diarrhoe**:
   * Diarrhea caused by treatment.
4. **Alopezie**:
   * Hair loss (alopecia) due to chemotherapy.
5. **Hans-Fuß-Syndrom**:
   * Hand-foot syndrome as a side effect.
6. **KM-Depression**:
   * Bone marrow depression (reduced blood cell production).
7. **Neurotoxizität**:
   * Neurological toxicity.
8. **Ototoxizität**:
   * Hearing loss or damage caused by treatment.
9. **AZ Verschlechterung**:
   * General deterioration in the patient’s condition.
10. **Sonstige Nebenwirkungen**:
    * Other side effects not listed.
11. **Sonstige Nebenwirkungen Text**:
    * Text field for specifying additional side effects.

### **Performance Status**

1. **ECOG-Stadium**:
   * ECOG performance status assessing functional ability.
2. **Karnofsky-Index (%)**:
   * Karnofsky performance score expressed as a percentage.

### **Molecular Markers**

1. **HER-2 Status**:
   * HER-2 receptor status, relevant in some cancers.
2. **Mikrosatelliten**:
   * Microsatellite instability, a marker in certain cancers.

### **Treatment Implementation**

1. **Umsetzung Chemotherapie ungewiss**:
   * Indicates uncertainty regarding the implementation of chemotherapy.

This comprehensive list captures the key aspects of palliative chemotherapy, focusing on treatment planning, execution, side effects, and patient outcomes.